International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi

Summary

The purpose of this study is to evaluate immunogenicity, epidemiological efficacy and safety of medicinal product GamEvac-Combi - Combined Vector-Based Vaccine against Ebola Virus Disease, 0.5 ml+0.5 ml/dose

Timeline

Start

2017-08-03

Primary completion

2019-12-31

Completion

2020-07-31

Publications

• Logunov DY, Dolzhikova IV, Boiro MY, Kovyrshina AV, Dzharullaeva AS, Erokhova AS, Grousova DM, Tukhvatulin AI, Izhaeva FM, Simakova YV, Ordzhonikidze MK, Lubenets NL, Zubkova OV, Scheblyakov DV, Esmagambetov IB, Shmarov MM, Semikhin AS, Tukhvatulina NM, Shcherbinin DN, Tutykhina IL, Prokhorov GS, Khovaev AA, Demidova TN, Malishev NA, Merkulova LN, Voronina OL, Fedyakina IT, Kisteneva LB, Kolobukhina LV, Mishin DV, Elakov AL, Ermolova EI, Krasnoslobodtsev KG, Larichev VF, Kruzhkova IS, Burmistrov EM, Sheremet AB, Tokarskaya EA, Gromov AV, Reshetnikov DA, Fisun AI, Kotiv BN, Ovchinnikov DV, Ivchenko EV, Zhdanov KV, Zakharenko SM, Solovev AN, Ivanov AM, Sukachev VS, Gudkov RV, Maltsev OV, Gabdrakhmanov IA, Barsukov AV, Vashchenkov VV, Demianenko NI, Ignatev SB, Asiamov KV, Kirichenko NN, Liubimov AV, Volkov II, Kriukov EV, Bazarnov NK, Kolodiazhnaia VA, Kolomoets EV, Syromyatnikova SI, Chifanov DE, Andrus AF, Kutaev DA, Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia. Front Immunol. 2025 Mar 20;16:1487039. doi: 10.3389/fimmu.2025.1487039. eCollection 2025.

Drugs

Indications